enalapril
A single-center, prospective double-blind randomized trial was conducted to       compare the efficacy and safety of the calcium channel blocker nisoldipine in a       sustained release coat-core formulation (CC), titrated from 10 mg to 40 mg daily,       with the angiotensin converting enzyme inhibitor enalapril, titrated from 10 to       40 mg daily, in the treatment of black South African patients with severe       hypertension (sitting diastolic blood pressure [DBP] between 115 and 140 mm Hg,       confirmed by 24-h ambulatory blood pressure monitoring).
A single-center, prospective double-blind randomized trial was conducted to       compare the efficacy and safety of the calcium channel blocker nisoldipine in a       sustained release coat-core formulation (CC), titrated from 10 mg to 40 mg daily,       with the angiotensin converting enzyme inhibitor  @SUBJECT$ , titrated from 10 to       40 mg daily, in the  @PREDICAT$  of black South African  @OBJECT$  with severe       hypertension (sitting diastolic blood pressure [DBP] between 115 and 140 mm Hg,       confirmed by 24-h ambulatory blood pressure monitoring).